Home › Research › Digital health tools
β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline
Hammond TC, Xing X, Wang C, Ma D, Nho K, Crane PK, Elahi F, Ziegler DA et al.. Communications biology, 2020-07-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Clinical trials focusing on therapeutic candidates that modify β-amyloid (Aβ) have repeatedly failed to treat Alzheimer's disease (AD), suggesting that Aβ may not be the optimal target for treating AD. The evaluation of Aβ, tau, and neurodegenerative (A/T/N) biomarkers has been proposed for classifying AD. However, it remains unclear whether disturbances in each arm of the A/T/N framework contribute equally throughout the progression of AD. Here, using the random forest machine learning method to analyze participants in the Alzheimer's Disease Neuroimaging Initiative dataset, we show that A/T/N biomarkers show varying importance in predicting AD development, with elevated biomarkers of Aβ and tau better predicting early dementia status, and biomarkers of neurodegeneration, especially glucose hypometabolism, better predicting later dementia status. Our results suggest that AD treatments may also need to be disease stage-oriented with Aβ and tau as targets in early AD and glucose metabolism as a target in later AD.
What this study adds
Evidence grade: Low
This analysis found that elevated β-amyloid and tau better predicted early dementia status while glucose hypometabolism better predicted later dementia status, suggesting treatments may need to be stage-oriented. It proposes targets for future treatment research but does not itself test any treatment, cure, or prevention for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hammond, T. C., Xing, X., Wang, C., Ma, D., Nho, K., Crane, P. K., et al. (2020). β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. Communications biology. https://doi.org/10.1038/s42003-020-1079-x
Vancouver
Hammond TC, Xing X, Wang C, Ma D, Nho K, Crane PK, et al. β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. Communications biology. 2020. doi:10.1038/s42003-020-1079-x. PMID: 32632135.
BibTeX
@article{hammond2020-32632135,
author = {Hammond, T. C. and Xing, X. and Wang, C. and Ma, D. and Nho, K. and Crane, P. K. and Elahi, F. and Ziegler, D. A. and others},
title = {{β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline}},
journal = {Communications biology},
year = {2020},
doi = {10.1038/s42003-020-1079-x},
pmid = {32632135},
url = {https://doi.org/10.1038/s42003-020-1079-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Clinical trials focusing on therapeutic candidates that modify β-amyloid (Aβ) have repeatedly failed to treat Alzheimer's disease (AD), suggesting that Aβ may not be the optimal target for treating AD.
- Our results suggest that AD treatments may also need to be disease stage-oriented with Aβ and tau as targets in early AD and glucose metabolism as a target in later AD.
Why it matters
This analysis found that elevated β-amyloid and tau better predicted early dementia status while glucose hypometabolism better predicted later dementia status, suggesting treatments may need to be stage-oriented. It proposes targets for future treatment research but does not itself test any treatment, cure, or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Communications biology) |
| Journal's citation record | 1 / 4 | Communications Biology: journal h-index 142 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 107 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.4 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 4 / 6 | Cited 9.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 46 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Ai‐Ling Lin: h-index 20 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32632135) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s42003-020-1079-x
- PubMed: 32632135
- Original source →
- Free full text: Communications Biology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 26.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Digital health tools from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.